# NCT07365241 (NCT07365241)

> A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07365241
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AbbVie
- Conditions: Small Cell Lung Cancer
- Interventions: ABBV-706; Topotecan; Topotecan; Lurbinectedin; Amrubicin
- Enrollment: 531
- Primary outcome: Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct07365241